Reglan (metoclopramide) is used to treat gastrointestinal disorders and nausea. Research has shown Reglan can significantly increase the risk of developing a neurological syndrome called tardive dyskinesia. Tardive dyskinesia causes involuntary repetitive movements.
The Food and Drug Administration began requiring Reglan and other metoclopramide drugs to carry a black box warning alerting consumers to the risk in February of 2009. Lawyers are pursuing litigation on behalf of patients affected by Reglan or metoclopramide use.